Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Type of study
Publication year range
1.
Eur J Med Chem ; 234: 114275, 2022 Apr 15.
Article in English | MEDLINE | ID: mdl-35306290

ABSTRACT

Zika virus (ZIKV) is a mosquito-borne flavivirus and outbreaks of ZIKV have been reported in Africa, Americas and other parts of the world lately. The ZIKV epidemic has received extensive attention due to its ability to cause serious medical consequences and complications such as microcephaly and Guillain-Barre syndrome in recent years. Up to now, there are no specific treatments or vaccines available for ZIKV infection, which highlights the urgent need for developing new therapies. In this work, we designed and synthesized a series of novel 6-methyl-7-acetylenenyl-7-deazapurine nucleoside analogs as potential inhibitors of ZIKV replication. The biological activities against ZIKV replication were evaluated and the structure-activity relationship (SAR) was also studied. Among the compounds evaluated, nucleoside analog 38 (EC50 = 2.8 ± 0.8 µM, EC90 = 6.8 ± 2.3 µM) showed the most potent anti-ZIKV activity with low cytotoxicity (CC50 = 54.1 ± 6.9 µM) in an A549 based cellular model. The inhibitory activity of 38 was about 5 times more potent than the positive control NITD008. Notably, 38 showed similar inhibition potency against different ZIKV strains (ZG-01 and MR766) in a variety of host cell types including SNB19, A549, Huh7, Vero. In addition, 38 (Kd = 1.87 µM) has a stronger affinity to ZIKV RNA-dependent RNA polymerase (RdRp) protein than NITD008 (Kd = 3.43 µM) in the non-phosphorylation assay. These results indicated that compound 38 may serve as a promising candidate in future anti-ZIKV drug discovery.


Subject(s)
Zika Virus Infection , Zika Virus , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Chlorocebus aethiops , Nucleosides/pharmacology , Purines , Vero Cells , Virus Replication , Zika Virus Infection/drug therapy
2.
Nat Commun ; 9(1): 368, 2018 01 25.
Article in English | MEDLINE | ID: mdl-29371594

ABSTRACT

During development, the formation of a mature, well-functioning heart requires transformation of the ventricular wall from a loose trabecular network into a dense compact myocardium at mid-gestation. Failure to compact is associated in humans with congenital diseases such as left ventricular non-compaction (LVNC). The mechanisms regulating myocardial compaction are however still poorly understood. Here, we show that deletion of the Ino80 chromatin remodeler in vascular endothelial cells prevents ventricular compaction in the developing mouse heart. This correlates with defective coronary vascularization, and specific deletion of Ino80 in the two major coronary progenitor tissues-sinus venosus and endocardium-causes intermediate phenotypes. In vitro, endothelial cells promote myocardial expansion independently of blood flow in an Ino80-dependent manner. Ino80 deletion increases the expression of E2F-activated genes and endothelial cell S-phase occupancy. Thus, Ino80 is essential for coronary angiogenesis and allows coronary vessels to support proper compaction of the heart wall.


Subject(s)
Adenosine Triphosphatases/metabolism , Endothelium, Vascular/metabolism , Heart Defects, Congenital/metabolism , Neovascularization, Pathologic/metabolism , ATPases Associated with Diverse Cellular Activities , Adenosine Triphosphatases/genetics , Animals , Coronary Vessels/metabolism , DNA Helicases/genetics , DNA Helicases/metabolism , DNA-Binding Proteins , Endocardium/metabolism , Endocardium/pathology , Endothelial Cells/enzymology , Endothelial Cells/metabolism , Endothelium, Vascular/pathology , Heart Defects, Congenital/genetics , Heart Ventricles/metabolism , Heart Ventricles/pathology , Humans , Mice, Knockout , Mice, Transgenic , Myocardium/metabolism , Myocardium/pathology , Neovascularization, Pathologic/genetics
3.
Antiviral Res ; 149: 95-105, 2018 01.
Article in English | MEDLINE | ID: mdl-29129706

ABSTRACT

Dengue fever, caused by four distinct serotypes of dengue virus (DENV-1 to -4), has become the fastest spreading human infectious disease in recent years. Despite extensive efforts, there is no specific antiviral treatment approved for dengue until now. Nucleoside inhibitors represent an actively pursued area to develop small-molecule anti-dengue virus agents. In this study, we designed and synthesized a series of 7-deazapurine nucleoside derivatives and evaluated their anti-DENV activity. Our design strategy and structure activity relationship studies revealed 6e as the most potent inhibitor (EC50 = 2.081 ± 1.102 µM) of DENV replication. 6e suppressed RNA levels and DENV E protein expression, without causing any apparent cytotoxicity in A549 and HepG2 cells (CC50 = 150.06 ± 11.42 µM, SI = 72.11 in A549 cells, and CC50 = 146.47 ± 11.05 µM and SI = 63.7 in HepG2 cells). In addition, 6e showed similar inhibition potency against four serotypes of DENV, suggesting that it restrains some evolutionarily conserved targets essential for DENV replication. We conceive that 6e may serve as a promising lead compound for anti-DENV drug development.


Subject(s)
Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Dengue Virus/drug effects , Drug Design , Purines/chemical synthesis , Purines/pharmacology , Animals , Antiviral Agents/chemistry , Cell Line , Cells, Cultured , Dengue Virus/classification , Dose-Response Relationship, Drug , Humans , Molecular Structure , Purines/chemistry , Serogroup , Structure-Activity Relationship
4.
Chem Biol Drug Des ; 89(3): 420-427, 2017 03.
Article in English | MEDLINE | ID: mdl-27589335

ABSTRACT

Novel dasatinib analogues as DDR1 and DDR2 inhibitors were designed and synthesized. The synthesized compounds were screened for DDR1 and DDR2 kinase inhibitory and cancer cell proliferation inhibitory activities. Some of the compounds showed the potent inhibitory activities against both DDR1 and DDR2, as well as anticancer activity in low nanomolar range against K562 cell line; especially, compound 3j demonstrated significantly better inhibitory potency than the parental dasatinib against both DDRs and also demonstrated the potent inhibitory activity against K562 cell lines (IC50 values of 2.26±0.46 nm for DDR1, 7.04±2.90 nm for DDR2, and 0.125±0.017 nm for K562 cell line).


Subject(s)
Dasatinib/analogs & derivatives , Discoidin Domain Receptor 1/antagonists & inhibitors , Discoidin Domain Receptor 2/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Binding Sites , Cell Proliferation/drug effects , Chemistry Techniques, Synthetic , Dasatinib/metabolism , Discoidin Domain Receptor 1/metabolism , Discoidin Domain Receptor 2/metabolism , Drug Screening Assays, Antitumor , Humans , Hydrogen Bonding , K562 Cells/drug effects , Molecular Docking Simulation , Piperazine , Piperazines/chemistry , Protein Kinase Inhibitors/chemical synthesis
5.
Yao Xue Xue Bao ; 47(5): 580-7, 2012 May.
Article in Chinese | MEDLINE | ID: mdl-22811999

ABSTRACT

Pyrimidine derivatives have been the subject of much attention in pesticide and medicine fields owing to their unique biological properties. Particularly, a large number of these compounds have recently been reported to show substantial antitumor activities, and some of them have been investigated in clinical trials. Although these structurally novel compounds have a common chemical moiety of a pyrimidine ring, there are a variety of mechanisms of their antitumor action, such as, inhibition of cyclin-dependent-kinases, inhibition of protein tyrosine kinase, inhibition of carbonic anhydrases, inhibition of dihydrofolate reductase and disruption of microtubule assembly. In this paper, we described the latest advances in the research of such pyrimidine derivatives as antitumor drug according to their action on targets.


Subject(s)
Antineoplastic Agents , Cyclin-Dependent Kinases/antagonists & inhibitors , Neoplasms , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyrimidines , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carbonic Anhydrase Inhibitors/pharmacology , Cell Proliferation/drug effects , Folic Acid Antagonists/pharmacology , Humans , Neoplasms/drug therapy , Neoplasms/pathology , Pyrimidines/chemistry , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Tetrahydrofolate Dehydrogenase/pharmacology , Tubulin Modulators/pharmacology , Tubulin Modulators/therapeutic use
6.
Eur J Med Chem ; 54: 813-22, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22809558

ABSTRACT

A series of novel isoindoline-1,3-diones containing 1,2,4-triazole moiety were synthesized via a one-pot reaction. Bioassay indicated that compounds 33, 35, 37 and 39 exhibited much higher activities against Botryodiplodia theobromae than commercial fungicide triadimefon at the dosage of 150 mg/L. Most interestingly, compounds 36, 37 and 45 displayed much stronger antitumor activities against four human cell lines than positive control Fluorouracil. Particularly, compound 37 had four-fold improvement compared to Fluorouracil in inhibiting A549 and HepG2 cell proliferation with IC(50) values of 6.76 and 9.44 µM, respectively. Further flow-activated cell sorting analysis revealed that compound 37 displayed apoptosis-inducing effect on HepG2 cells in a dose-dependent manner. These encouraging results could be helpful for the development of new antitumor compounds.


Subject(s)
Antifungal Agents/chemical synthesis , Antifungal Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Isoindoles/chemical synthesis , Isoindoles/pharmacology , Triazoles/chemistry , Antifungal Agents/chemistry , Antineoplastic Agents/chemistry , Cell Cycle/drug effects , Cell Line, Tumor , Chemistry Techniques, Synthetic , Fungi/drug effects , Humans , Isoindoles/chemistry
7.
Bioorg Med Chem Lett ; 22(13): 4471-4, 2012 Jul 01.
Article in English | MEDLINE | ID: mdl-22647723

ABSTRACT

A series of 3,4-disubstituted-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazoles and some novel 5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles bearing 3,4,5-trimethoxyphenyl moiety were synthesized and screened for their anticancer activity. The preliminary bioassay results indicated that compounds 14 and 16 showed much stronger cytotoxicity than Doxorubicin against HepG2 cell lines with IC(50) values of 0.58 and 3.17 µM, respectively. Meanwhile compound 16 also exhibited a broad spectrum of antitumor activity against MCF-7 and MKN45 with IC(50) values of 10.92 and 13.79 µM, respectively.


Subject(s)
Antineoplastic Agents/chemical synthesis , Thiadiazoles/chemistry , Triazoles/chemistry , Antineoplastic Agents/chemistry , Antineoplastic Agents/toxicity , Apoptosis/drug effects , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Hep G2 Cells , Humans , Molecular Conformation , Structure-Activity Relationship , Thiadiazoles/chemical synthesis , Thiadiazoles/toxicity , Triazoles/chemical synthesis , Triazoles/toxicity
8.
Acta Crystallogr Sect E Struct Rep Online ; 68(Pt 6): o1854, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-22719619

ABSTRACT

In the title compound, C(21)H(19)NO(3)S(2), the dihedral angles formed between the thia-zole ring and the adjacent benzene ring and the other benzene ring are 1.58 (3) and 76.48 (6)°, respectively. The crystal structure features a weak C-H⋯O inter-action.

9.
Nan Fang Yi Ke Da Xue Xue Bao ; 31(5): 875-7, 2011 May.
Article in Chinese | MEDLINE | ID: mdl-21602147

ABSTRACT

OBJECTIVE: To synthesize cyclin-dependent kinase (CDKs) inhibitors and assay their antitumor activities. METHODS: A series of pyrimidines containing different arylamino and 1-(methylsulfonyl)piperidin moieties were designed by combining the segments 1-(methylsulfonyl)piperidin and pyrimidine heterocycles according to the super-position principle of the reinforcement of biological activities. RESULTS: Their structures were characterized by MS and 1H NMR spectra and all the synthesized compounds were screened for their antimicrobial activity with MTT assay. CONCLUSION: The preliminary bioassay showed that compound 3 b displayed good antitumor activity (IC(50)=13.6 µmol/L). The preliminary structure activity relationship analysis of these analogues suggest that the steric factor may have important impact on the anti-tumor activity.


Subject(s)
Pyrimidines/chemistry , Pyrimidines/chemical synthesis , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Drug Screening Assays, Antitumor , Humans , Pyrimidines/pharmacology , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...